Immunocore Holdings Earns Buy Rating from H.C. Wainwright Amid Strong Growth and Advancements

Immunocore Holdings' strong revenue growth and clinical advancements justify a Buy rating from H.C. Wainwright analyst Patrick Trucchio. The company's KIMMTRAK has exceeded expectations, and Immunocore is making progress in its clinical trials, including Phase 3 trials for tebentafusp in earlier-stage diseases and advancements in its PRAME franchise. With a robust cash position and diverse clinical pipeline, Trucchio believes Immunocore is well-positioned for sustained growth.

Immunocore Holdings' robust financial performance and clinical advancements have garnered a strong Buy rating from H.C. Wainwright analyst Patrick Trucchio. The company's lead product, KIMMTRAK (tebentafusp), has shown impressive revenue growth, with a 30% year-over-year increase in net product revenue for the second quarter of 2025. This growth supports the company's pipeline expansion, particularly in autoimmune programs.

In addition to KIMMTRAK's success, Immunocore is making significant progress in its clinical trials. The company has two Phase 3 trials for tebentafusp in earlier-stage diseases and advancements in its PRAME franchise. The Phase 3 TEBE-AM trial is on track to complete enrollment in the first half of 2026, and the PRISM-MEL-301 trial is enrolling patients for first-line advanced cutaneous melanoma. The company's diverse clinical pipeline, including efforts in infectious diseases and autoimmune programs, further bolsters its growth prospects.

Immunocore's strong cash position, with $883 million as of June 30, 2025, and a robust financial performance, as highlighted by a 32% year-over-year increase in revenue for the first half of 2025, underscore its potential for sustained growth. Trucchio believes the company is well-positioned for future success, reinforcing his Buy rating and $100 price target.

Another analyst, Leerink Partners, also maintained a Buy rating on the stock with a $60.00 price target, further validating Immunocore's potential. The company's global expansion of KIMMTRAK, potential expansion into 2L+ advanced cutaneous melanoma, and the potential for a functional cure in infectious diseases contribute to its promising outlook.

References:
[1] https://www.tipranks.com/news/ratings/immunocore-holdings-strong-revenue-growth-and-clinical-advancements-justify-buy-rating-ratings?mod=mw_quote_news
[2] https://www.globenewswire.com/news-release/2025/08/07/3129043/0/en/Immunocore-reports-second-quarter-financial-results-and-provides-a-business-update.html